Author | PHARM EXEC

Articles

Lilly Launches Online Training for Patient Advocates

Pharmaceutical Executive

Article

An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.

Outlook “Gloomy” for TB Investment

Pharmaceutical Executive

Article

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) - at the time the first TB drug approval in 40 years - “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.

European Physicians Have "Insufficient Knowledge of Biosimilars"

Pharmaceutical Executive

Article

European physicians have insufficient knowledge of biosimilars, according to a survey carried out by the Alliance for Safe Biologic Medicines (ASBM).

China Supply Chain Progress Still Hampered by Corruption, Pollution, Working Conditions

Pharmaceutical Executive

Article

Supply chains risks in China still include extremely high levels of corruption, environmental pollution issues and slow working conditions reforms, according to new analysis from Sedex.